BIOPSEE, a Hubei-based microendoscope specialist, has raised tens of millions of renminbi in a Series A+ financing round led by Ezhou Changda Investment, Suzhou High-Tech Venture Capital, Suzhou Kejicheng Venture Capital, and SND Group. The funds will support research and development, scaled manufacturing, and clinical applications of confocal microendoscope products.
Company Background
Founded in 2014, BIOPSEE focuses on minimally invasive diagnosis and treatment technologies, including real-time visual biopsy capabilities. The firm secured China’s first confocal microendoscope approval in 2019 and a second-generation system approval in 2021. Its products are used in over 30 Class 3A hospitals across 16 provinces.
Clinical Development
As of this month, BIOPSEE has three ongoing visual biopsy clinical studies led by Beijing Friendship Hospital and other top hospitals. An additional 12 trials are set to launch by year-end, advancing its confocal microendoscope pipeline.-Fineline Info & Tech
